PDF(Pubmed)
Abstract：
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a highly aggressive subtype of T-ALL. No standard chemotherapy regimen exists for patients with recurrent/refractory (R/R) ETP-ALL; in these patients, the primary goal of salvage therapy is to achieve remission as a foundation for consolidation and intensification treatments. This study reports cases of two patients with R/R ETP-ALL who underwent salvage therapy of venetoclax combined with the CAG regimen and achieved complete remission in the bone marrow. Flow cytometry results were negative for minimal residual disease. Both patients were bridged to allogeneic hematopoietic stem cell transplantation (HSCT) and in complete remission over a 3-year follow-up period. These cases show that the use of venetoclax combined with the CAG regimen may offer patients with R/R ETP-ALL an opportunity for allogeneic HSCT.
摘要：
早期T细胞前体急性淋巴细胞白血病（ETP-ALL）是T-ALL的一种高度侵袭性亚型。对于复发/难治性（R/R）ETP-ALL患者，没有标准的化疗方案；在这些患者中，挽救治疗的主要目标是实现缓解，作为巩固和强化治疗的基础。本研究报告了2例R/RETP-ALL患者接受维奈托克联合CAG方案的挽救治疗并实现骨髓完全缓解的病例。流式细胞术检测结果为微小残留病阴性。两名患者均与异基因造血干细胞移植（HSCT）桥接，并在3年的随访期内完全缓解。这些病例表明，使用venetoclax联合CAG方案可能为R/RETP-ALL患者提供同种异体HSCT的机会。
